Literature DB >> 22345695

Factors associated with compliance to lipid-lowering treatment in China.

Gaoqiang Xie1, M Justin S Zaman, Phyo K Myint, Lirong Liang, Liancheng Zhao, Yangfeng Wu.   

Abstract

BACKGROUND: There are an estimated 200 million people in China with dyslipidaemia. We sought to explore factors that influence compliance to treatment of dyslipidaemia, using a multi-centre sample in China.
METHODS: Through review of medical notes and direct interviews at two points in time (2006 and 2007) of 2094 patients in 27 hospitals receiving lipid-lowering therapy since 2004, 1890 patients were recruited who had been on treatment for more than one year. Good compliance (GC) was defined as days taking lipid-lowering drugs/total days of follow-up ≥ 80%. Logistic regression models were used to assess factors associated with GC.
RESULTS: In patients with one, two and three years of treatment respectively, GC was greater in those with higher versus lower medical insurance cover - odds ratios 2.8 (95%CI 2.2-3.7), 2.0 (1.5-2.7), 4.3 (2.3-8.1); in patients in province-level versus county-level hospitals-2.0 (1.5-2.6), 2.9 (2.0-4.1), 4.6 (1.8-12.0); in patients treated by non-cardiology physicians compared to cardiologists -1.7 (1.1-2.5), 2.0 (1.3-3.0), 4.0 (1.5-10.3) and in patients using a statin versus other forms of medication for dyslipidaemia -1.7 (1.2-2.2), 1.7 (1.2-2.3), 4.4 (2.3-8.5).
CONCLUSIONS: Better medical insurance cover, care in a province-level hospital rather than county-level hospital, treatment by a non-cardiologist and use of a statin were associated with better compliance to lipid-lowering treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345695     DOI: 10.1177/2047487312438847

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  7 in total

1.  Comparative and Combined Effects of Epigallocatechin-3-gallate and Caffeine in Reducing Lipid Accumulation in Caenorhabditis elegans.

Authors:  Yan Wang; Yu-Fan Xiang; Ai-Lin Liu
Journal:  Plant Foods Hum Nutr       Date:  2022-05-28       Impact factor: 3.921

2.  Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL-cholesterol in clinical pathways for acute coronary syndromes studies.

Authors:  Yihong Sun; Gaoqiang Xie; Anushka Patel; Shenshen Li; Wei Zhao; Xingzi Yang; Tao Wu; Min Li; Xian Li; Xin Du; Rong Hu; Yong Huo; Dayi Hu; Run Ling Gao; Yangfeng Wu
Journal:  Clin Cardiol       Date:  2018-09-22       Impact factor: 2.882

3.  The relationship between apolipoprotein CIII gene polymorphism and serum lipid levels in Han Chinese males.

Authors:  Shu Su; Min Tang; Mingjun Zhang; Chunquan Cheng; Xiaojun Tang
Journal:  Meta Gene       Date:  2013-11-15

4.  Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.

Authors:  Mingming Li; Jian Cai; Ping Zhang; Chunhua Fei; Feng Xu
Journal:  Front Pharmacol       Date:  2017-01-10       Impact factor: 5.810

5.  Characteristics of patients with dyslipidemia treated in routine care setting in China.

Authors:  Gordon Liu; Jason Shepherd; Pratik Rane; Zhongyun Zhao; Hollie Bailey; Nathan Williams; Yi Qian
Journal:  J Drug Assess       Date:  2019-10-23

Review 6.  Determinants of Non-Adherence to the Medications for Dyslipidemia: A Systematic Review.

Authors:  João Lopes; Paulo Santos
Journal:  Patient Prefer Adherence       Date:  2021-08-24       Impact factor: 2.711

7.  Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework.

Authors:  Abdullah A Alfaifi; Leanne Lai; Abdullah U Althemery
Journal:  PLoS One       Date:  2021-08-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.